Alimera Sciences to Report First Quarter 2020 Financial Results on Wednesday, April 29, 2020 and Provide Corporate Update
April 24 2020 - 8:00AM
Alimera Sciences, Inc. (Nasdaq: ALIM) (Alimera), a leader in the
commercialization and development of prescription ophthalmology
treatments for the management of retinal diseases, announces that
it will report first quarter 2020 financial results on Wednesday,
April 29, 2020 after the market close.
Management will host a conference call at 9:00 AM ET on
Thursday, April 30, 2020, to review financial results and provide
an update on corporate developments. Following management’s
formal remarks, there will be a question and answer session.
Participants are asked to pre-register for the call through the
following link: http://dpregister.com/10142450. Please note that
registered participants will receive their dial in number upon
registration and will dial directly into the call without delay.
Those without internet access or unable to pre-register may dial in
by calling: 1-866-777-2509 (domestic) or 1-412-317-5413
(international). All callers should dial in approximately 10
minutes prior to the scheduled start time and ask to be joined into
the Alimera Sciences call. The conference call will also be
available through a live webcast, which can be accessed through the
following link:
https://services.choruscall.com/links/alimera200430.html which is
also available through the company’s website at
http://client.irwebkit.com/alimerasciences/events.
A webcast replay of the call will be available approximately one
hour after the end of the call through July 30, 2020. The
replay can be accessed through the above links or by calling
1-877-344-7529 (domestic) or 1-412-317-0088 (international) and
using access code 10142450. The telephonic replay will be available
until May 30, 2020.
About Alimera Sciences, Inc.
Alimera Sciences is a pharmaceutical company that specializes in
the commercialization and development of prescription ophthalmic
pharmaceuticals. Alimera is presently focused on diseases affecting
the back of the eye, or retina, because these diseases are not well
treated with current therapies and affect millions of people in our
aging populations. For more information, please visit
www.alimerasciences.com.
For press inquiries:Jules Abrahamfor Alimera
Sciences 917-885-7378julesa@coreir.com |
For investor inquiries:Scott Gordonfor Alimera
Sciences scottg@coreir.com |
Alimera Sciences (NASDAQ:ALIM)
Historical Stock Chart
From Aug 2024 to Sep 2024
Alimera Sciences (NASDAQ:ALIM)
Historical Stock Chart
From Sep 2023 to Sep 2024